10:27 AM
 | 
Oct 12, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

Despite manufacturing concern, Acacia still expects 1H19 launch for PONV therapy

Acacia Pharma Group plc (Euronext:ACPH) said FDA raised a concern related to manufacturing deficiencies in a complete response letter issued for an NDA seeking approval of Barhemsys amisulpride to treat and prevent postoperative nausea and vomiting.

Acacia said it still anticipates a...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >